Starving liver tumors: new combo aims to stop cancer from eating itself
NCT ID NCT05842174
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 32 times
Summary
This study tests whether adding a drug that blocks a cancer cell survival process called autophagy can make standard TACE therapy more effective for liver cancer. TACE cuts off the tumor's blood supply, but cancer cells often survive by eating their own parts for energy. The trial enrolls about 93 adults with unresectable liver cancer to see if this combination improves local tumor control and boosts the immune system's attack on the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
RECRUITINGPhiladelphia, Pennsylvania, 19104-4551, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.